样式: 排序: IF: - GO 导出 标记为已读
-
Multi-modality management of defects in the gastrointestinal tract: Where the endoscope meets the scalpel: Endoscopic vacuum therapy in the upper gastrointestinal tract Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-03-06 Lisanne M.D. Pattynama, Wietse J. Eshuis, Stefan Seewald, Roos E. Pouw
Transmural defects in the upper gastrointestinal (GI) tract, such as anastomotic leakage and oesophageal perforations, are associated with significant morbidity and mortality risks. Endoscopic vacuum therapy (EVT) is an efficient and safe treatment option for these patients. With the growing use of EVT in the upper GI tract, it is important to share expertise on the topic. This review explores the
-
Endoscopic management of surgical complications Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-03-06 Mayank Goyal, Anmol Bains, Yadwinder Singh, Fnu Deepali, Anmol Singh, Shubham Sood, Navtej S. Buttar
While the endoscopic management of surgical complications like leaks, fistulas, and perforations is rapidly evolving, its core principles revolve around closure, drainage, and containment. Effectively managing these conditions relies on several factors, such as the underlying cause, chronicity of the lesion, tissue viability, co-morbidities, availability of devices, and expertise required to perform
-
Endoscopic resection of residual rectal neoplasia after definitive chemoradiotherapy for rectal cancer Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-28 Robert Klimkowski, Jakub Krzyzkowiak, Nastazja Dagny Pilonis, Krzysztof Bujko, Michal F. Kaminski
The conventional approach to treating locally advanced rectal cancer, commonly defined as cT3 or cT4 primary tumors or with nodal metastases, involves chemoradiation (CRT) followed by surgical resection. There is a growing recognition of the potential for nonsurgical management following CRT or total neoadjuvant therapy (TNT), which allows for organ preservation. “Watch and wait” strategy may be considered
-
Management of ERCP complications Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-27 Partha Pal, Mohan Ramchandani
Managing complications of ERCP poses a significant clinical challenge to endoscopists. ERCP complications can occur even after all preventive measures, which can lead to significant morbidity and even mortality. Major complications include pancreatitis, bleeding, perforation, cholangitis, and sedation-related adverse events. Early recognition of post-ERCP pancreatitis (PEP) is feasible by monitoring
-
The endoscopic management of oesophageal strictures Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-27 Benjamin Charles Norton, Apostolis Papaefthymiou, Nasar Aslam, Andrea Telese, Charles Murray, Alberto Murino, Gavin Johnson, Rehan Haidry
An oesophageal stricture refers to a narrowing of the oesophageal lumen, which may be benign or malignant. The cardinal feature is dysphagia, and this may result from intrinsic oesophageal disease or extrinsic compression. Oesophageal strictures can be further classified as simple or complex depending on stricture length, location, diameter, and underlying aetiology. Many endoscopic options are now
-
Management of perforations during endoscopic resection Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-27 Ludovico Alfarone, Marco Spadaccini, Alessandro Repici, Cesare Hassan, Roberta Maselli
Despite the evolution in tools and techniques, perforation is still one of the most pernicious adverse events of therapeutic endoscopy with potentially huge consequences. As advanced endoscopic resection techniques are worldwide spreading, endoscopists must be ready to manage intraprocedural perforations. In fact, immediate endoscopic closure through a prompt diagnosis represents the first-line option
-
Management after non-curative endoscopic resection of T1 rectal cancer Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-23 Hao Dang, Daan A. Verhoeven, Jurjen J. Boonstra, Monique E. van Leerdam
Since the introduction of population-based screening, increasing numbers of T1 rectal cancers are detected and removed by local endoscopic resection. Patients can be cured with endoscopic resection alone, but there is a possibility of residual tumor cells remaining after the initial resection. These can be located intraluminally at the resection site or extraluminally in the form of (lymph node) metastases
-
Management of non-curative endoscopic resection of T1 colon cancer Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-21 Linn Bernklev, Jens Aksel Nilsen, Knut Magne Augestad, Øyvind Holme, Nastazja Dagny Pilonis
Endoscopic resection techniques enable en-bloc resection of T1 colon cancers. A complete removal of T1 colon cancer can be considered curative when histologic examination of the specimens shows none of the high-risk factors for lymph nodes metastases. Criteria predicting lymph nodes metastases include deep submucosal invasion, poor differentiation, lymphovascular invasion, and high-grade tumor budding
-
Curative criteria for endoscopic treatment of oesophageal squamous cell cancer Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-17 Toshiro Iizuka
Endoscopic treatment of early oesophageal squamous cell carcinoma is widely accepted. ESD (Endoscopic Submucosal Dissection), which allows en bloc resection regardless of size, provides resected specimens that facilitate histological evaluation of curability. In the histological investigation, the determination of tumor depth, lymphovascular involvement, and lateral and vertical margins play a great
-
Multimodal cancer treatment with endoscopy Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-16 Michal F. Kaminski, Nastazja Dagny Pilonis
-
Multimodal treatment with endoscopic ablation and systemic therapy for cholangiocarcinoma Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-16 Zaheer Nabi, Michał Żorniak, D Nageshwar Reddy
Cholangiocarcinoma (CCA) are primary malignancies of biliary system and usually unresectable at the time of diagnosis. As a consequence, majority of these cases are candidates for palliative care. With the advances in chemotherapeutic agents and multidisciplinary care, the survival rate has improved in cases with inoperable malignant biliary obstruction. As a consequence, there is a need to provide
-
Curative criteria for endoscopic treatment of gastric cancer Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-03 João A. Cunha Neves, Pedro G. Delgado-Guillena, Patrícia Queirós, Diogo Libânio, Enrique Rodríguez de Santiago
Endoscopic treatment, particularly endoscopic submucosal dissection, has become the primary treatment for early gastric cancer. A comprehensive optical assessment, including white light endoscopy, image-enhanced endoscopy, and magnification, are the cornerstones for clinical staging and determining the resectability of lesions. This paper discusses factors that influence the indication for endoscopic
-
Management of high risk T1 esophageal adenocarcinoma following endoscopic resection Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-03 Philippe Leclercq, Raf Bisschops, Jacques J.G.H.M. Bergman, Roos E. Pouw
High-risk T1 esophageal adenocarcinoma (HR-T1 EAC) is defined as T1 cancer, with one or more of the following histological criteria: submucosal invasion, poorly or undifferentiated cancer, and/or presence of lympho-vascular invasion. Esophagectomy has long been the only available treatment for these HR-T1 EACs and was considered necessary because of a presumed high risk of lymph node metastases up
-
Endoscopic resection for residual oesophageal neoplasia after definitive chemoradiotherapy Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-01-31 Judith Honing, Arjun D. Koch, Peter D. Siersema, Manon Spaander
Definitive chemoradiation is the recommended treatment for locally advanced, irresectable oesophageal cancer and a valid alternative to neoadjuvant chemoradiotherapy (CRT) with surgery in oesophageal squamous cell cancer (OSCC) patients. In case of locoregional recurrence, salvage treatment can be considered in fit and resectable patients. Salvage surgery is a valid option but associated with significant
-
Multimodal management of foregut neuroendocrine neoplasms Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-02 Yichan Zhou, James Weiquan Li, Noriya Uedo
The foregut, which includes the esophagus, stomach and duodenum, represents one of the most common sites for neuroendocrine neoplasms. These are highly heterogenous with different risk of progression depending on location, cell-type of origin, size, grade and other factors. Various endoscopic and imaging modalities exist to inform therapeutic decision-making, which may be in the form of surgical or
-
Complications and management of interventional endoscopic ultrasound: A critical review Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-02 Carlo Fabbri, Davide Scalvini, Giuffrida Paolo, Cecilia Binda, Aurelio Mauro, Chiara Coluccio, Stefano Mazza, Margherita Trebbi, Francesca Torello Viera, Andrea Anderloni
In the last decades, Endoscopic ultrasound (EUS) has rapidly grown and evolved from being mainly a diagnostic procedure, to being an interventional and therapeutic tool in several pathological clinical scenarios. With the progressive growth in technical expertise and dedicated devices, interventional endoscopic ultrasound procedures (IEUSP) have shown high rates of technical and clinical success, together
-
Management of iatrogenic perforations during endoscopic interventions in the hepato-pancreatico-biliary tract Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-02-01 Kirsten Boonstra, Rogier P. Voermans, Roy L.J. van Wanrooij
Endoscopic retrograde cholangiopancreaticography (ERCP) and endoscopic ultrasound (EUS) guided interventions are among the most challenging procedures performed by interventional endoscopists and are associated with a significant risk of complications. Early recognition and classification of perforations allows immediate therapy which improves clinical outcomes. In this article we review the different
-
Curative criteria for endoscopic treatment of oesophageal adenocarcinoma Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-01-30 AnnemijnD.I. Maan, Prateek Sharma, Arjun D. Koch
The incidence of oesophageal adenocarcinoma has been increasing rapidly in the Western world. A well-known risk factor for developing this type of tumour is reflux disease, which can cause metaplasia from the squamous cell mucosa to columnar epithelium (Barrett's Oesophagus) which can progress to dysplasia and eventually adenocarcinoma. With the rise of the incidence of oesophageal adenocarcinoma,
-
Management of high risk T1 gastric adenocarcinoma following endoscopic resection Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-01-30 Jéssica Chaves, Diogo Libânio, Pedro Pimentel-Nunes
Endoscopic submucosal dissection has revolutionized the treatment of early gastric cancer. However, cases that do not meet the curability criteria have a higher risk of lymph node metastasis and salvage surgery is still considered the next treatment approach to increase the chance of cure. Nevertheless, not all high-risk resections entail the same level of risk, emphasizing the utmost importance of
-
Curative criteria for endoscopic treatment of colorectal cancer Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2024-01-25 Lucille Quénéhervé, Mathieu Pioche, Jérémie Jacques
As endoscopic treatment enables en bloc resection of T1 colorectal cancers, the risk of recurrence, often assimilated to the risk of lymph node metastases, must be assessed in order to offer patients an additional treatment if this risk is deemed significant. The curative criteria currently used by most guidelines are depth of invasion <1 mm, well or moderately differentiated tumour, absence of lympho-vascular
-
Editorial Board Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-12-14
Abstract not available
-
Copyright Information Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-12-14
Abstract not available
-
Table of Contents Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-12-14
Abstract not available
-
Prognostic models and autoimmune liver diseases Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-12-01 Daphne D'Amato, Marco Carbone
Autoimmune liver diseases (AILDs) are complex diseases with unknown causes and immune-mediated pathophysiology. In primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) disease modifying drugs are available which improve patient quality and quantity of life. In primary sclerosing cholangitis (PSC) no medical therapy is available and the only accepted treatment is liver transplantation (LT)
-
Prognostic modelling in IBD Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-11-29 Peter Rimmer, Tariq Iqbal
In the ideal world prognostication or predicting disease course in any chronic condition would allow the clinician to anticipate disease behaviour, providing crucial information for the patient and data regarding best use of resources. Prognostication also allows an understanding of likely response to treatment and the risk of adverse effects of a treatment leading to withdrawal in any individual patient
-
Editorial Board Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-10-16
Abstract not available
-
Table of Contents Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-10-16
Abstract not available
-
Copyright Information Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-10-16
Abstract not available
-
Prognostic models: What the statistician wants the clinician to know Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-10-09 Elisa Allen, Matthew L. Robb
Prognostic model building is a process that begins much earlier than data analysis and ends later than when a model is reached. It requires careful delineation of a clinical question, methodical planning of the approach and attentive exploration of the data before attempting model building. Once following these important initial steps, the researcher may postulate a model to describe the process of
-
Scoring systems for risk stratification in upper and lower gastrointestinal bleeding Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-10-07 Franco Radaelli, Simone Rocchetto, Alessandra Piagnani, Alberto Savino, Dhanai Di Paolo, Giulia Scardino, Silvia Paggi, Emanuele Rondonotti
Several scoring systems have been developed for both upper and lower GI bleeding to predict the bleeding severity and discriminate between low-risk patients, who may be suitable for outpatient management, and those who would likely need hospital-based interventions and are at high risk for adverse outcomes. Risk scores created to identify low-risk patients (namely the Glasgow Blatchford Score and the
-
Colorectal cancer diagnostic biomarkers: Beyond faecal haemoglobin Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-09-23 A. Krishnamoorthy, R. Arasaradnam
Colorectal cancer (CRC) is the third most common cancer worldwide, and the second commonest cause of cancer deaths worldwide. One of the most important prognostic factors, and thus a potential target for improving cancer care, is the stage of cancer at diagnosis. Earlier stage diagnosis is associated with better prognosis and longer survival times after treatment. At the same time, the use of targeted
-
Prognostic models in alcohol-related liver disease and alcohol-related hepatitis Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-09-11 Jessica Ann Musto, Michael Ronan Lucey
Alcohol-associated liver disease (ALD) and alcohol-associated hepatitis (AH) are dynamic disorders whose prognosis can be challenging to determine. A number of prognostic models have been developed to determine likelihood of death, when to refer for liver transplant (LT) and the role for glucocorticoids. Often these models were created with a specific application in mind but were found to have additional
-
Colorectal cancer: From prevention to treatment Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-09-09 Joaquín Cubiella, Cristina Regueiro-Expósito
Abstract not available
-
Prognostic models – Their use and abuse Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-09-08 James Neuberger, Lorenzo Fuccio
Abstract not available
-
Prognostic models in end stage liver disease Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-31 A. Ferrarese, M. Bucci, A. Zanetto, M. Senzolo, G. Germani, M. Gambato, F.P. Russo, P. Burra
Cirrhosis is a major cause of death worldwide, and is associated with significant health care costs. Even if milestones have been recently reached in understanding and managing end-stage liver disease (ESLD), the disease course remains somewhat difficult to prognosticate. These difficulties have already been acknowledged already in the past, when scores instead of single parameters have been proposed
-
Editorial Board Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-29
Abstract not available
-
Table of Contents Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-29
Abstract not available
-
Copyright Information Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-29
Abstract not available
-
Models and scores to predict adequacy of bowel preparation before colonoscopy Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-16 Romane Fostier, Georgios Tziatzios, Antonio Facciorusso, Apostolis Papaefthymiou, Marianna Arvanitakis, Konstantinos Triantafyllou, Paraskevas Gkolfakis
-
Updates in the diagnosis and management of small-bowel tumors Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-12 Erasmia Vlachou, Apostolos Koffas, Christos Toumpanakis, Martin Keuchel
Small-bowel tumors represent a rare entity comprising 0.6% of all new cancer cases in the US, and only 3% of all gastrointestinal neoplasms. They are a heterogenous group of neoplasms comprising of about forty different histological subtypes with the most common being adenocarcinoma, neuroendocrine tumors, stromal tumors and lymphomas. Their incidence has been reportedly increasing over recent years
-
Diagnosis and management of mid-gut (small-bowel) diseases: The state of the art in 2023 Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-10 Edward J. Despott, Alberto Murino
Abstract not available
-
The evolving role of small-bowel capsule endoscopy Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-09 Silvia Pecere, Michele Francesco Chiappetta, Livio Enrico Del Vecchio, Edward Despott, Xavier Dray, Anastasios Koulaouzidis, Lorenzo Fuccio, Alberto Murino, Emanuele Rondonotti, Manon Spaander, Cristiano Spada
Abstract not available
-
The evolving role of device-assisted enteroscopy: The state of the art as of August 2023 Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-09 Hironori Yamamoto, Edward J. Despott, Begoña González-Suárez, Marco Pennazio, Klaus Mönkemüller
Device-assisted enteroscopy (DAE), balloon-assisted enteroscopy (BAE) in particular, has become a routine endoscopic procedure which has revolutionized our approach to small-bowel disease. Evidence demonstrating the efficacy and safety of BAE spans over 22-years of experience, making it an established pillar of minimally invasive care. The robust evidence for BAE's safety and efficacy has now been
-
Updates in the diagnosis and management of small-bowel Crohn's disease Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-09 Cristina Carretero, Alejandro Bojorquez, Rami Eliakim, Nikolaos Lazaridis
Abstract not available
-
pT1 colorectal cancer: A treatment dilemma Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-07 Angelo Brunori, Maria Daca-Alvarez, Maria Pellisé
The implementation of population screening programs for colorectal cancer (CRC) has led to a considerable increase in the prevalence pT1-CRC originating on polyps amenable by local treatments. However, a high proportion of patients are referred for unnecessary oncological surgeries without a clear benefit in terms of survival. Selecting the appropriate endoscopic resection technique in the moment of
-
Predictive models in EUS/ERCP Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-02 Barbara Lattanzi, Daryl Ramai, Paraskevas Gkolfakis, Antonio Facciorusso
Predictive models (PMs) in endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) have the potential to improve patient outcomes, enhance diagnostic accuracy, and guide therapeutic interventions. This review aims to summarize the current state of predictive models in ERCP and EUS and their clinical implications. To be considered useful in clinical practice a PM should
-
Safe, non-surgical retrieval of foreign bodies from the small bowel Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-08-02 Maria Elena Riccioni, Clelia Marmo
Abstract not available
-
Updates in the diagnosis and management of non-ampullary small-bowel polyposis Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-07-22 Laura Lucaciu, Tomonori Yano, Jean Christophe Saurin
Advances in endoscopic instruments and techniques changed the strategy of diagnosis and management for non-ampullary small-bowel polyposis. In patients with Peutz-Jeghers syndrome, gastrointestinal surveillance using capsule endoscopy should commence no later than eight years old. Small bowel polyps >15 mm should be treated to prevent intussusception. Recently, endoscopic ischemic polypectomy and endoscopic
-
Jejunal access for enteral nutrition: A practical guide for percutaneous endoscopic gastrostomy with jejunal extension and direct percutaneous endoscopic jejunostomy Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-07-17 Amélie Bourgeois, Paraskevas Gkolfakis, Lucia Fry, Marianna Arvanitakis
For patients requiring long-term (>4 weeks) jejunal nutrition, jejunal medication delivery, or decompression, a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) or a direct percutaneous endoscopic jejunostomy (DPEJ) may be indicated. PEG-J is the preferred option if a PEG tube is already in place or if simultaneous gastric decompression and jejunal nutrition are needed. DPEJ is recommended
-
Lights and shadows in the early-onset colorectal cancer management and research: An integrative perspective – Physician scientist with patient advocates Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-07-14 José Perea, Phuong Gallagher, Annie Delores
Early-onset colorectal cancer (age under 50 years) (EOCRC) is an entity of undeniable importance, both because of its growing incidence, and the population it affects. Other current reviews emphasize the essential points regarding the clinical management and knowledge of its molecular bases. However, we intend to go one step further. With the increased significance of patient participation and disease
-
The evolving role of device-assisted enteroscopy Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-07-04 Hironori Yamamoto, Begoña González-Suárez, Klaus Mönkemüller
Device-assisted enteroscopy is now considered a routine endoscopy and we have accumulated almost 20 years of experience using deep enteroscopy to investigate disorders of the small bowel and the pancreatobiliary tract in patients with surgically altered upper gastrointestinal tract anatomy. This chapter is written by the developers and pioneers of the techniques of deep enteroscopy. We present the
-
Updates in the diagnosis and management of non-ampullary small-bowel polyposis Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-07-04 Laura Lucaciu, Tomonori Yano, Jean Christophe Saurin
Advances in endoscopic instruments and techniques changed the strategy of diagnosis and management for non-ampullary small-bowel polyposis. In patients with Peutz-Jeghers syndrome, gastrointestinal surveillance using capsule endoscopy should commence no later than eight years old. Small bowel polyps >15 mm should be treated to prevent intussusception. Recently, endoscopic ischemic polypectomy and endoscopic
-
Rationale for organized Colorectal cancer screening programs Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-07-05 Carlo Senore, Iris Lansdorp-Vogelaar, Lucie de Jonge, Linda Rabeneck
Colorectal cancer (CRC) is a major health problem and it is expected that the number of persons diagnosed with CRC and CRC-related deaths will continue to increase. However, recent years have shown reductions in CRC incidence and mortality particularly among individuals aged 50 years and older which can be attributed to screening, improvements in patients’ management, closer adherence to treatment
-
Surveillance after colorectal polyp resection Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-07-05 Sandra Baile-Maxía, Rodrigo Jover
Post-polypectomy surveillance has proven to reduce colorectal cancer (CRC) incidence in patients with high-risk polyps, but it implies a major burden on colonoscopy units. Therefore, it should be targeted to individuals with a higher risk. Different societies have published guidelines on surveillance after resection of polyps, with notable discrepancies among them, and many recommendations come from
-
Diagnosis and management of small-bowel bleeding Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-07-04 Marco Pennazio, Pablo Cortegoso Valdivia, Konstantinos Triantafyllou, Ian M. Gralnek
Small-bowel (SB) bleeding is a challenging problem for the clinician, presenting many pitfalls in both diagnosis and subsequent treatment. Videocapsule endoscopy (VCE) and device-assisted enteroscopy (DAE) have revolutionized the approach to the patient with SB bleeding, allowing for the endoscopic diagnosis and management of what was previously only a surgical matter. The patients’ assessment in SB
-
Updates in the diagnosis and management of coeliac disease Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-07-04 Mohamed G. Shiha, Stefania Chetcuti Zammit, Luca Elli, David S. Sanders, Reena Sidhu
Coeliac disease is a common autoimmune disorder induced by ingesting gluten, the protein component of wheat, barley, and rye. It is estimated that one-in-hundred people worldwide have coeliac disease, of whom the majority remain undiagnosed. Coeliac disease is characterized by a wide range of gastrointestinal and extraintestinal symptoms but can also present asymptomatically. Diagnosing coeliac disease
-
Updates on the diagnosis and management of cryptogenic multifocal ulcerative stenosing enteropathy (CMUSE) and non-steroidal enteropathy Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-07-04 Tom G. Moreels, Ayaskanta Singh
Crohn's disease and coeliac disease are well-known to induce ulcerations in the small-bowel. However, there is a group of very rare chronic ulcerative conditions of the small intestine that has emerged from the intestinal black box nearly 70 years ago, and that has gained interest with the advent of small-bowel capsule endoscopy and device-assisted enteroscopy. These distinct ulcerative enteropathies
-
Colorectal cancer in symptomatic patients: How to improve the diagnostic pathway Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-06-21 William Hamilton, Sarah E.R. Bailey
Even in countries with national screening programmes for colorectal cancer, most cancers are identified after the patient has developed symptoms. The patients present these symptoms usually to primary care, or in some countries to specialist care. In either healthcare setting, the clinician has to consider cancer to be a possibility, then to perform triage investigations, followed by definitive investigation
-
What is the optimal type and dose of physical activity for colorectal cancer prevention? Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-05-24 Samuel T. Orange
Epidemiological evidence shows that higher levels of physical activity reduce the relative risk of colon cancer by up to 20%. To design optimal physical activity interventions for primary prevention, it is important to understand how the specific characteristics of physical activity (type, intensity, overall volume) influence the magnitude of colon cancer risk reduction. Improving our understanding
-
Preventive strategies in familial and hereditary colorectal cancer Best Pract. Res. Clin. Gastroenterol. (IF 3.2) Pub Date : 2023-05-24 Zachariah H. Foda, Pooja Dharwadkar, Bryson W. Katona
Colorectal cancer is a leading cause of cancer-related deaths worldwide. While most cases are sporadic, a significant proportion of cases are associated with familial and hereditary syndromes. Individuals with a family history of colorectal cancer have an increased risk of developing the disease, and those with hereditary syndromes such as Lynch syndrome or familial adenomatous polyposis have a significantly